{"id":"stempeucel","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Infection"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The product consists of ex vivo expanded bone marrow-derived mesenchymal stem cells that secrete bioactive factors including cytokines and growth factors. These cells modulate the immune response, reduce inflammatory markers, and promote angiogenesis and tissue repair in damaged tissues. The mechanism relies on the therapeutic properties of living cells rather than a single molecular target.","oneSentence":"Stempeucel® is an allogeneic mesenchymal stem cell therapy that promotes tissue regeneration and reduces inflammation through paracrine signaling and immunomodulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:09:40.761Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Critical limb ischemia"},{"name":"Diabetic foot ulcers"}]},"trialDetails":[{"nctId":"NCT05854641","phase":"PHASE4","title":"Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Peripheral Arterial Disease","status":"RECRUITING","sponsor":"Cell Biopeutics Resources Sdn Bhd","startDate":"2024-01-01","conditions":"Critical Limb Ischemia, Peripheral Arterial Disease","enrollment":10},{"nctId":"NCT05854615","phase":"PHASE4","title":"Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease","status":"RECRUITING","sponsor":"Cell Biopeutics Resources Sdn Bhd","startDate":"2024-01-01","conditions":"Critical Limb Ischemia, Buerger's Disease","enrollment":3},{"nctId":"NCT03056742","phase":"PHASE2","title":"A Clinical Trial to Study the Efficacy and Safety of Stempeucel® in Patients With CLI Due to Buergers Disease","status":"WITHDRAWN","sponsor":"Stempeutics Research Pvt Ltd","startDate":"2017-02-20","conditions":"Critical Limb Ischemia Due to Buerger's Disease","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Stempeucel®","genericName":"Stempeucel®","companyName":"Cell Biopeutics Resources Sdn Bhd","companyId":"cell-biopeutics-resources-sdn-bhd","modality":"Biologic","firstApprovalDate":"","aiSummary":"Stempeucel® is an allogeneic mesenchymal stem cell therapy that promotes tissue regeneration and reduces inflammation through paracrine signaling and immunomodulation. Used for Critical limb ischemia, Diabetic foot ulcers.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}